查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球抗体发现服务市场（按类型、宿主、分子、最终用户和地区划分）- 预测至 2030 年
市场调查报告书
商品编码
1811734

全球抗体发现服务市场（按类型、宿主、分子、最终用户和地区划分）- 预测至 2030 年

Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 380 Pages | 订单完成后即时交付

价格

抗体发现服务市场预计将从 2024 年的 19 亿美元成长到 2030 年的 35.4 亿美元，预测期内的复合年增长率为 13.3%。

调查范围
调查年份 2024-2030
基准年 2024
预测期 2025-2030
对价单位 金额（十亿美元）
部分 按类型、宿主、分子、最终用户和地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲、海湾合作委员会国家

抗体发现服务市场的发展受到双特异性抗体 (bsAbs) 和 ADC 等先进形式的发展，以及创业投资资金和策略伙伴关係关係的不断增加的推动。此外，人工智慧的整合和端到端服务模式的采用正在简化工作流程、提高效率并加速该领域的创新。

抗体发现服务市场-IMG1

市场细分为小鼠/大鼠、兔、鸡、骆驼科动物和其他宿主。到2024年，小鼠/大鼠市场将占据抗体发现免疫和宿主管理服务市场的最大份额。由于这些动物物种与人类基因相似、成本效益高以及高度优化的饲养和实验方案，它们仍然是首选。它们的广泛应用反映了临床前抗体发现中成熟的免疫工作流程和强大的宿主管理基础设施。此外，小鼠和大鼠模型的广泛使用支持可扩展且高度可重复的免疫服务，有助于使用试验的免疫技术快速生成抗体。这种细分还使服务供应商能够根据已充分錶征的动物系统定制免疫策略和宿主处理方法，从而提高可预测性和效率。考虑到这些优势，小鼠/大鼠宿主细分市场将成为抗体发现服务市场中免疫和宿主管理服务的主导细分市场。

抗体发现服务市场细分为製药和生物技术公司、学术和研究机构以及其他。受抗体治疗计画研发活动规模的推动，製药和生技公司在 2024 年占据了抗体发现服务市场的最大份额。製药和生物技术公司管理着广泛的产品线，需要在肿瘤学、免疫学、感染疾病和其他治疗领域中不断发现新的候选抗体。这些公司正在大力投资专业服务供应商提供的噬菌体展示、融合瘤和基于人工智慧的筛检平台等先进技术。对外包的高需求也反映了简化时间表、降低内部成本和访问内部无法提供的功能的需求。此外，製药和生物技术公司正在寻求合作伙伴关係和协作，以扩大对发现平台的访问，使他们能够有效地从目标识别进展到临床前评估。广泛的治疗重点、大量投资以及对外部专业知识的依赖，使这些公司成为 2024 年市场需求的主要企业贡献者。

2024年，北美占据了抗体发现服务市场的最大份额。这一地位得益于从事抗体开发的製药和生物技术公司、研究机构和合约服务供应商的高度集中。政府机构和私人投资者为生物医学研究提供的充足资金创造了对发现服务的稳定需求。北美还拥有成熟的法律规范，支持基于抗体的疗法的发展，从而实现了从药物发现到临床评估的有效过渡。先进的研究基础设施、熟练的劳动力和成熟的技术基础进一步增强了该地区利用和扩展抗体发现服务的能力。此外，活性化以及产学研之间的密切合作也促进了需求的持续成长。这些因素共同作用，使北美成为2024年全球抗体发现服务市场的关键地区。

本报告研究了全球抗体发现服务市场，提供了按类型、宿主、分子、最终用户和地区分類的趋势信息，以及参与市场的公司概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章 市场概况

  • 介绍
  • 市场动态

第六章 产业趋势

  • 影响客户业务的趋势/中断
  • 价值链分析
  • 生态系分析
  • 投资金筹措场景
  • 技术分析
  • 专利分析
  • 2025-2026年主要会议和活动
  • 案例研究分析
  • 监管分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 人工智慧/生成式人工智慧对抗体发现服务市场的影响

第七章抗体发现服务市场（按类型）

  • 介绍
  • 目标识别和检验
  • 抗体工程与优化
  • 抗原设计与生产
  • 免疫和宿主控制
  • 其他的

第 8 章抗体发现服务市场（按主机）

  • 介绍
  • 小鼠和大鼠
  • 兔子
  • 鸡
  • 骆驼科动物
  • 其他的

第九章抗体发现服务市场（按分子）

  • 介绍
  • 单株抗体
  • 多株抗体
  • 其他的

第 10 章抗体发现服务市场（依最终用户）

  • 介绍
  • 製药和生物技术公司
  • 学术研究机构
  • 其他的

第 11 章抗体发现服务市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东
    • 中东宏观经济展望
    • 海湾合作委员会国家
    • 其他的
  • 非洲

第十二章 竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 2020-2024年收益分析
  • 2024年市场占有率分析
  • 公司估值矩阵：2024 年关键参与企业
  • 公司估值矩阵：Start-Ups/中小企业，2024 年
  • 估值和财务指标
  • 品牌/服务比较
  • 竞争场景

第十三章：公司简介

  • 主要参与企业
    • WUXI BIOLOGICS
    • THERMO FISHER SCIENTIFIC INC.
    • CHARLES RIVER LABORATORIES
    • EVOTEC
    • BIOCYTOGEN
    • EUROFINS SCIENTIFIC
    • SHANGHAI CHEMPARTNER
    • AURIGENE PHARMACEUTICAL SERVICES LTD.（DR. REDDY'S LABORATORIES）
    • SINO BIOLOGICAL, INC.
    • SAMSUNG BIOLOGICS
    • GENSCRIPT
    • CURIA GLOBAL, INC.
    • TWIST BIOSCIENCE
    • HARBOUR BIOMED
    • ARAGEN LIFE SCIENCES LTD.
    • DANAHER CORPORATION
    • CREATIVE BIOLABS
    • VIVA BIOTECH
    • IMMUNOPRECISE ANTIBODIES LTD.
    • FUSION ANTIBODIES
  • 其他公司
    • ABZENA
    • ALLOY THERAPEUTICS, INC.
    • INTEGRAL MOLECULAR
    • BIODURO
    • SYNBIO TECHNOLOGIES
    • ABSOLUTE ANTIBODY
    • ADIMAB
    • ISOGENICA
    • ABLEXIS
    • FAIRJOURNEY

第十四章 附录

Product Code: PH 9491

The antibody discovery services market is expected to reach 3.54 billion in 2030 from USD 1.90 billion in 2024, at a CAGR of 13.3% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsType, Technology, Flowrate, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries

Factors propelling the antibody discovery services market include the development of advanced formats such as bispecific antibodies (bsAbs) and ADCs, alongside rising venture funding and strategic partnerships. Moreover, the integration of AI and adoption of end-to-end service models are streamlining workflows, enhancing efficiency, and accelerating innovation in the field.

Antibody Discovery Services Market - IMG1

The mice & rats segment accounted for the largest share of the antibody discovery immunization & host management services market in 2024.

The market is segmented into mice & rats, rabbits, chickens, camelids, and other hosts. In 2024, the mouse & rat segment accounted for the largest share of the antibody discovery immunization & host management services market. These species remain the preferred choice due to their genetic similarity to humans, cost-effectiveness, and highly optimized breeding and experimental protocols. Their widespread use reflects well-established immunization workflows and robust host management infrastructure in preclinical antibody discovery efforts. Furthermore, the prevalence of mouse and rat models supports scalable, reproducible immunization services, facilitating rapid antibody generation through tried-and-tested immunological methods. This segmentation also enables service providers to tailor immunization strategies and host handling practices to well-characterized animal systems, enhancing predictability and efficiency. Collectively, these advantages cement the mouse & rat host segment as the dominant segment in immunization and host management services within the antibody discovery services market.

In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market.

The antibody discovery services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the antibody discovery services market, driven by the scale of research and development activities directed toward therapeutic antibody programs. These companies manage extensive pipelines that require continuous discovery of new antibody candidates across oncology, immunology, infectious diseases, and other therapeutic areas. They invest heavily in advanced technologies such as phage display, hybridoma, and AI-based screening platforms provided by specialized service providers to support this. The high demand for outsourcing also reflects the need to streamline timelines, reduce internal costs, and access capabilities unavailable in-house. In addition, pharmaceutical and biotechnology firms pursue partnerships and collaborations that expand access to discovery platforms, enabling them to move efficiently from target identification to preclinical evaluation. The combination of broad therapeutic focus, large-scale investments, and reliance on external expertise established these companies as the leading contributors to market demand in 2024.

In 2024, North America accounted for the largest share of the antibody discovery services market.

North America accounted for the largest share of the antibody discovery services market in 2024. The region accounted for this position due to its concentration of pharmaceutical and biotechnology companies, research institutes, and contract service providers engaged in antibody development. Extensive funding for biomedical research from government agencies and private investors created a steady demand for discovery services. North America also benefits from a mature regulatory framework that supports the advancement of antibody-based therapeutics, enabling efficient progression from discovery to clinical evaluation. The presence of advanced research infrastructure, a skilled workforce, and established technology platforms further strengthened the region's capacity to utilize and expand antibody discovery services. In addition, high clinical trial activity and strong collaborations between industry and academia contributed to sustained demand. Collectively, these factors positioned North America as the leading region in the global antibody discovery services market in 2024.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  • By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
  • By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), Aragen Life Sciences Ltd. (India) are some of the key companies offering Antibody Discovery Services products.

Research Coverage

This research report categorizes the Antibody Discovery Services market by Type [Target Identification & Validation, Antibody Engineering & Optimization (Phage/Yeast Display Technology, Hybridoma Technology, Single-Cell Technologies, Other Technologies), Antigen Design & Production, Immunization & Host Management, Other Services], Immunization & Host Management By Host (Mice & Rats, Rabbits, Chickens, Camelids, Other Hosts), Molecule (Monoclonal Antibodies, Polyclonal Antibodies, Other Molecules), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Antibody Discovery Services market. A detailed analysis of the key industry players has provided insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the antibody discovery services market. This report covers a competitive analysis of top players and upcoming startups in the Antibody Discovery Services market ecosystem.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Antibody Discovery Services market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the Antibody Discovery Services market. This report covers the competitive analysis of upcoming startups in the Antibody Discovery Services market ecosystem.

Key Benefits of Buying the Report

This report provides a detailed picture of the antibody discovery services market. It aims to estimate the size and future growth potential of the market across different segments such as the type, host, molecule, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (Development of new antibody formats, growing number of ADCs in clinical trials, rising funds for venture and partnership for biologics), restraints (High cost & complexity of biologics discovery, competition from alternative modalities, patent cliffs and rise of biosimilars), opportunities (end-to-end discovery-to-IND service bundles, integration of AI and automation in discovery workflow), Challenges (reagent & raw material supply chain bottlenecks, fragmented data and workflow infrastructure)

  • Service Development/Innovation: Detailed insights on newly launched Services, and technological assessment of the antibody discovery services market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the antibody discovery services market across varied regions.
  • Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the antibody discovery services market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), among others in the antibody discovery services market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.4 YEARS CONSIDERED
    • 1.4.1 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary data sources
      • 2.1.1.2 Key objectives of secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION
      • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.2 MnM repository analysis & primary interviews
      • 2.2.1.3 Insights from primary experts
      • 2.2.1.4 Segmental market size estimation by top-down approach
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

  • 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
  • 3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET
  • 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS

  • 4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024)
  • 4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030
  • 4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE
  • 4.6 UNMET NEEDS & WHITE SPACES
  • 4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
  • 4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS
  • 4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
    • 4.11.1 SUSTAINABILITY IMPACT
    • 4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES
  • 4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Development of bispecific antibodies and antibody fragments
      • 5.2.1.2 Rising number of antibody-drug conjugates in clinical trials
      • 5.2.1.3 Increasing venture and partnership funding for biologics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs and complexity of biologics discovery
      • 5.2.2.2 Competition from alternative modalities
      • 5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 End-to-end discovery-to-IND service bundles/one-stop shop models in antibody discovery
      • 5.2.3.2 Integration of AI and automation in discovery workflow
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Reagents and raw material supply chain bottlenecks
      • 5.2.4.2 Fragmented data and disjointed workflow infrastructure

6 INDUSTRY TRENDS

  • 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 6.2 VALUE CHAIN ANALYSIS
  • 6.3 ECOSYSTEM ANALYSIS
    • 6.3.1 RAW MATERIAL SUPPLIERS
    • 6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS
    • 6.3.3 END USERS
    • 6.3.4 REGULATORY BODIES
  • 6.4 INVESTMENT & FUNDING SCENARIO
    • 6.4.1 MAJOR INVESTMENTS AND FUNDING
  • 6.5 TECHNOLOGY ANALYSIS
    • 6.5.1 KEY TECHNOLOGIES
      • 6.5.1.1 Phage display platforms
      • 6.5.1.2 Hybridoma technology
      • 6.5.1.3 Single B-cell screening
    • 6.5.2 COMPLEMENTARY TECHNOLOGIES
      • 6.5.2.1 AI/ML-based protein structure prediction
      • 6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI)
      • 6.5.2.3 Cryo-electron microscopy (CRYO-EM)
    • 6.5.3 ADJACENT TECHNOLOGIES
      • 6.5.3.1 CRISPR-based functional genomics
      • 6.5.3.2 CHO cell line development
      • 6.5.3.3 In-vivo modelling
  • 6.6 PATENT ANALYSIS
    • 6.6.1 METHODOLOGY
    • 6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
    • 6.6.3 LIST OF KEY PATENTS
  • 6.7 KEY CONFERENCES & EVENTS, 2025-2026
  • 6.8 CASE STUDY ANALYSIS
    • 6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION
    • 6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS
    • 6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA
  • 6.9 REGULATORY ANALYSIS
    • 6.9.1 REGULATORY LANDSCAPE
      • 6.9.1.1 North America
      • 6.9.1.2 Europe
      • 6.9.1.3 Asia Pacific
      • 6.9.1.4 Rest of the World
    • 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.10 PORTER'S FIVE FORCES ANALYSIS
    • 6.10.1 BARGAINING POWER OF SUPPLIERS
    • 6.10.2 BARGAINING POWER OF BUYERS
    • 6.10.3 THREAT OF NEW ENTRANTS
    • 6.10.4 THREAT OF SUBSTITUTES
    • 6.10.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 6.11.2 KEY BUYING CRITERIA
  • 6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
    • 6.12.1 INTRODUCTION
    • 6.12.2 MARKET POTENTIAL OF AI

7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 TARGET IDENTIFICATION & VALIDATION
    • 7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH
  • 7.3 ANTIBODY ENGINEERING & OPTIMIZATION
    • 7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY
      • 7.3.1.1 Phage display technology
        • 7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth
      • 7.3.1.2 Hybridoma technology
        • 7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth
      • 7.3.1.3 Single-cell technologies
        • 7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth
      • 7.3.1.4 Other antibody engineering & optimization technologies
  • 7.4 ANTIGEN DESIGN & PRODUCTION
    • 7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH
  • 7.5 IMMUNIZATION & HOST MANAGEMENT
    • 7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH
  • 7.6 OTHER ANTIBODY DISCOVERY SERVICES

8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST

  • 8.1 INTRODUCTION
  • 8.2 MOUSE & RAT
    • 8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH
  • 8.3 RABBIT
    • 8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH
  • 8.4 CHICKEN
    • 8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET
  • 8.5 CAMELIDS
    • 8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH
  • 8.6 OTHER HOSTS

9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE

  • 9.1 INTRODUCTION
  • 9.2 MONOCLONAL ANTIBODIES
    • 9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET
  • 9.3 POLYCLONAL ANTIBODIES
    • 9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH
  • 9.4 OTHER MOLECULES

10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH
  • 10.3 ACADEMIC & RESEARCH INSTITUTES
    • 10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH
  • 10.4 OTHER END USERS

11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US to dominate antibody discovery services market during forecast period
    • 11.2.3 CANADA
      • 11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth
    • 11.3.3 UK
      • 11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion
    • 11.3.5 ITALY
      • 11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth
    • 11.3.6 SPAIN
      • 11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth
    • 11.4.3 JAPAN
      • 11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth
    • 11.4.4 INDIA
      • 11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market
    • 11.4.5 SOUTH KOREA
      • 11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth
    • 11.4.6 AUSTRALIA
      • 11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 UAE
        • 11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth
      • 11.6.2.2 Kingdom of Saudi Arabia
        • 11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth
      • 11.6.2.3 Rest of GCC Countries
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET
    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET
  • 12.3 REVENUE ANALYSIS, 2020-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Type footprint
      • 12.5.5.4 Host footprint
      • 12.5.5.5 Molecule footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.6.5.1 List of key startups/SMEs
      • 12.6.5.2 Competitive benchmarking of key startups/SMEs
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/SERVICE COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 SERVICE LAUNCHES
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 WUXI BIOLOGICS
      • 13.1.1.1 Business overview
      • 13.1.1.2 Services offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Deals
        • 13.1.1.3.2 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 THERMO FISHER SCIENTIFIC INC.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Services offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
        • 13.1.2.3.2 Expansions
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 CHARLES RIVER LABORATORIES
      • 13.1.3.1 Business overview
      • 13.1.3.2 Services offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 EVOTEC
      • 13.1.4.1 Business overview
      • 13.1.4.2 Services offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
        • 13.1.4.3.2 Contracts
        • 13.1.4.3.3 Expansions
        • 13.1.4.3.4 Other developments
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 BIOCYTOGEN
      • 13.1.5.1 Business overview
      • 13.1.5.2 Services offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Service launches
        • 13.1.5.3.2 Deals
        • 13.1.5.3.3 Expansions
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 EUROFINS SCIENTIFIC
      • 13.1.6.1 Business overview
      • 13.1.6.2 Services offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Expansions
    • 13.1.7 SHANGHAI CHEMPARTNER
      • 13.1.7.1 Business overview
      • 13.1.7.2 Services offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Deals
    • 13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES)
      • 13.1.8.1 Business overview
      • 13.1.8.2 Services offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Expansions
    • 13.1.9 SINO BIOLOGICAL, INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Services offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Deals
        • 13.1.9.3.2 Expansions
    • 13.1.10 SAMSUNG BIOLOGICS
      • 13.1.10.1 Business overview
      • 13.1.10.2 Services offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Service launches
    • 13.1.11 GENSCRIPT
      • 13.1.11.1 Business overview
      • 13.1.11.2 Services offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Service launches
        • 13.1.11.3.2 Deals
    • 13.1.12 CURIA GLOBAL, INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Services offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
        • 13.1.12.3.2 Other developments
    • 13.1.13 TWIST BIOSCIENCE
      • 13.1.13.1 Business overview
      • 13.1.13.2 Services offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Service launches
        • 13.1.13.3.2 Deals
        • 13.1.13.3.3 Expansions
    • 13.1.14 HARBOUR BIOMED
      • 13.1.14.1 Business overview
      • 13.1.14.2 Services offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Deals
        • 13.1.14.3.2 Other developments
    • 13.1.15 ARAGEN LIFE SCIENCES LTD.
      • 13.1.15.1 Business overview
      • 13.1.15.2 Services offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Expansions
    • 13.1.16 DANAHER CORPORATION
      • 13.1.16.1 Business overview
      • 13.1.16.2 Services offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Deals
    • 13.1.17 CREATIVE BIOLABS
      • 13.1.17.1 Business overview
      • 13.1.17.2 Services offered
    • 13.1.18 VIVA BIOTECH
      • 13.1.18.1 Business overview
      • 13.1.18.2 Services offered
    • 13.1.19 IMMUNOPRECISE ANTIBODIES LTD.
      • 13.1.19.1 Business overview
      • 13.1.19.2 Services offered
      • 13.1.19.3 Recent developments
        • 13.1.19.3.1 Deals
    • 13.1.20 FUSION ANTIBODIES
      • 13.1.20.1 Business overview
      • 13.1.20.2 Services offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 ABZENA
    • 13.2.2 ALLOY THERAPEUTICS, INC.
    • 13.2.3 INTEGRAL MOLECULAR
    • 13.2.4 BIODURO
    • 13.2.5 SYNBIO TECHNOLOGIES
    • 13.2.6 ABSOLUTE ANTIBODY
    • 13.2.7 ADIMAB
    • 13.2.8 ISOGENICA
    • 13.2.9 ABLEXIS
    • 13.2.10 FAIRJOURNEY

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 ANTIBODY DISCOVERY SERVICES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS IN ANTIBODY DISCOVERY SERVICES MARKET
  • TABLE 3 ANTIBODY DISCOVERY SERVICES MARKET: RISK ANALYSIS
  • TABLE 4 KEY IP/PLATFORM ASSETS OF KEY PLAYERS, 2022-2025
  • TABLE 5 IMPACT ANALYSIS OF ANTIBODY DISCOVERY SERVICES MARKET DYNAMICS
  • TABLE 6 MAJOR VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS, 2025
  • TABLE 7 ROLE OF RAW MATERIAL SUPPLIERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
  • TABLE 8 ROLE OF ANTIBODY DISCOVERY SERVICE PROVIDERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
  • TABLE 9 ROLE OF END USERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
  • TABLE 10 ROLE OF REGULATORY BODIES IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
  • TABLE 11 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN ANTIBODY DISCOVERY SERVICES MARKET, 2014-2024
  • TABLE 12 LIST OF KEY PATENTS IN ANTIBODY DISCOVERY SERVICES MARKET
  • TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2025-DECEMBER 2026
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ANTIBODY DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES
  • TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%), BY TYPE
  • TABLE 20 KEY BUYING CRITERIA FOR MAJOR END USERS
  • TABLE 21 KEY PLAYERS IMPLEMENTING AI IN ANTIBODY DISCOVERY SERVICES
  • TABLE 22 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 23 TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 24 NORTH AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 25 EUROPE: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 LATIN AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 MIDDLE EAST: TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 29 GCC COUNTRIES: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 31 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 36 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 38 PHAGE DISPLAY TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 EUROPE: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 MIDDLE EAST: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 GCC COUNTRIES: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 NORTH AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 EUROPE: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 LATIN AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 MIDDLE EAST: HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 GCC COUNTRIES: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 EUROPE: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 LATIN AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 MIDDLE EAST: SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 GCC COUNTRIES: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 EUROPE: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 MIDDLE EAST: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 GCC COUNTRIES: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 EUROPE: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 LATIN AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 MIDDLE EAST: ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 GCC COUNTRIES: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 EUROPE: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 EUROPE: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 MIDDLE EAST: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 GCC COUNTRIES: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 88 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 103 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 110 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 117 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 124 ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 130 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET MONOCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 132 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 144 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 146 ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 151 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 152 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 154 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 161 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 168 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 170 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 171 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 174 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 175 US: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 US: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 177 US: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 178 US: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 179 US: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 180 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 CANADA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 182 CANADA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 183 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 184 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 185 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 188 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 189 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 190 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 191 EUROPE: KEY MACROINDICATORS
  • TABLE 192 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 GERMANY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 194 GERMANY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 195 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 196 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 197 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 UK: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 199 UK: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 200 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 201 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 202 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 203 FRANCE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 204 FRANCE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 205 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 206 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 207 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 ITALY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 209 ITALY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 210 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 211 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 212 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 213 SPAIN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 214 SPAIN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 215 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 216 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 217 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 REST OF EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 219 REST OF EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 220 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 221 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 229 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 230 CHINA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 231 CHINA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 232 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 233 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 234 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 235 JAPAN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 236 JAPAN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 237 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 238 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 239 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 INDIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 241 INDIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 242 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 243 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 244 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 245 SOUTH KOREA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 246 SOUTH KOREA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 247 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 248 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 249 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 AUSTRALIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 251 AUSTRALIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 252 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 253 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 254 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 255 REST OF ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 256 REST OF ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 257 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 258 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 259 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 260 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 261 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 262 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 263 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 264 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 265 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 266 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 267 BRAZIL: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 268 BRAZIL: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 269 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 270 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 271 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 272 MEXICO: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 273 MEXICO: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 274 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 275 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 276 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 277 REST OF LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 278 REST OF LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 279 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 280 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 281 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 282 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 283 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 284 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 285 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 286 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 287 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 288 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 291 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 292 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 293 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 294 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 UAE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 296 UAE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 297 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 298 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 299 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 KINGDOM OF SAUDI ARABIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 301 KINGDOM OF SAUDI ARABIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 302 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 303 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 304 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 305 REST OF GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 306 REST OF GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 307 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 308 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 309 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 REST OF MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 311 REST OF MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 312 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 313 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 314 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 315 AFRICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 316 AFRICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023-2030 (USD MILLION)
  • TABLE 317 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 318 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 319 AFRICA: KEY MACROINDICATORS
  • TABLE 320 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2022-AUGUST 2025
  • TABLE 321 ANTIBODY DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
  • TABLE 322 ANTIBODY DISCOVERY SERVICES MARKET: REGION FOOTPRINT
  • TABLE 323 ANTIBODY DISCOVERY SERVICES MARKET: TYPE FOOTPRINT
  • TABLE 324 ANTIBODY DISCOVERY SERVICES MARKET: HOST FOOTPRINT
  • TABLE 325 ANTIBODY DISCOVERY SERVICES MARKET: MOLECULE FOOTPRINT
  • TABLE 326 ANTIBODY DISCOVERY SERVICES MARKET: LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 327 ANTIBODY DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION
  • TABLE 328 ANTIBODY DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2022-AUGUST 2025
  • TABLE 329 ANTIBODY DISCOVERY SERVICES MARKET: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 330 ANTIBODY DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 331 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 332 WUXI BIOLOGICS: SERVICES OFFERED
  • TABLE 333 WUXI BIOLOGICS: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 334 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 335 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 336 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
  • TABLE 337 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 338 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 339 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 340 CHARLES RIVER LABORATORIES: SERVICES OFFERED
  • TABLE 341 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 342 EVOTEC: COMPANY OVERVIEW
  • TABLE 343 EVOTEC: SERVICES OFFERED
  • TABLE 344 EVOTEC: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 345 EVOTEC: CONTRACTS, JANUARY 2022-AUGUST 2025
  • TABLE 346 EVOTEC: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 347 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2022-AUGUST 2025
  • TABLE 348 BIOCYTOGEN: COMPANY OVERVIEW
  • TABLE 349 BIOCYTOGEN: SERVICES OFFERED
  • TABLE 350 BIOCYTOGEN: SERVICE LAUNCHES, JANUARY 2022-AUGUST 2025
  • TABLE 351 BIOCYTOGEN: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 352 BIOCYTOGEN: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 353 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 354 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 355 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 356 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
  • TABLE 357 SHANGHAI CHEMPARTNER: SERVICES OFFERED
  • TABLE 358 SHANGHAI CHEMPARTNER: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 359 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES): COMPANY OVERVIEW
  • TABLE 360 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES): SERVICES OFFERED
  • TABLE 361 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES): EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 362 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW
  • TABLE 363 SINO BIOLOGICAL, INC.: SERVICES OFFERED
  • TABLE 364 SINO BIOLOGICAL, INC.: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 365 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 366 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
  • TABLE 367 SAMSUNG BIOLOGICS: SERVICES OFFERED
  • TABLE 368 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022-AUGUST 2025
  • TABLE 369 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 370 GENSCRIPT: SERVICES OFFERED
  • TABLE 371 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2022-AUGUST 2025
  • TABLE 372 GENSCRIPT: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 373 CURIA GLOBAL, INC.: COMPANY OVERVIEW
  • TABLE 374 CURIA GLOBAL, INC.: SERVICES OFFERED
  • TABLE 375 CURIA GLOBAL, INC.: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 376 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2022-AUGUST 2025
  • TABLE 377 TWIST BIOSCIENCE: COMPANY OVERVIEW
  • TABLE 378 TWIST BIOSCIENCE: SERVICES OFFERED
  • TABLE 379 TWIST BIOSCIENCE: SERVICE LAUNCHES, JANUARY 2022-AUGUST 2025
  • TABLE 380 TWIST BIOSCIENCE: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 381 TWIST BIOSCIENCE: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 382 HARBOUR BIOMED: COMPANY OVERVIEW
  • TABLE 383 HARBOUR BIOMED: SERVICES OFFERED
  • TABLE 384 HARBOUR BIOMED: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 385 HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022-AUGUST 2025
  • TABLE 386 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
  • TABLE 387 ARAGEN LIFE SCIENCES LTD.: SERVICES OFFERED
  • TABLE 388 ARAGEN LIFE SCIENCES LTD.: EXPANSIONS, JANUARY 2022-AUGUST 2025
  • TABLE 389 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 390 DANAHER CORPORATION: SERVICES OFFERED
  • TABLE 391 DANAHER CORPORATION: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 392 CREATIVE BIOLABS: COMPANY OVERVIEW
  • TABLE 393 CREATIVE BIOLABS: SERVICES OFFERED
  • TABLE 394 VIVA BIOTECH: COMPANY OVERVIEW
  • TABLE 395 VIVA BIOTECH: SERVICES OFFERED
  • TABLE 396 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW
  • TABLE 397 IMMUNOPRECISE ANTIBODIES LTD.: SERVICES OFFERED
  • TABLE 398 IMMUNOPRECISE ANTIBODIES LTD.: DEALS, JANUARY 2022-AUGUST 2025
  • TABLE 399 FUSION ANTIBODIES: COMPANY OVERVIEW
  • TABLE 400 FUSION ANTIBODIES: SERVICES OFFERED
  • TABLE 401 ABZENA: COMPANY OVERVIEW
  • TABLE 402 ALLOY THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 403 INTEGRAL MOLECULAR: COMPANY OVERVIEW
  • TABLE 404 BIODURO: COMPANY OVERVIEW
  • TABLE 405 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 406 ABSOLUTE ANTIBODY: COMPANY OVERVIEW
  • TABLE 407 ADIMAB: COMPANY OVERVIEW
  • TABLE 408 ISOGENICA: COMPANY OVERVIEW
  • TABLE 409 ABLEXIS: COMPANY OVERVIEW
  • TABLE 410 FAIRJOURNEY: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 ANTIBODY DISCOVERY SERVICES MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 ANTIBODY DISCOVERY SERVICES MARKET: YEARS CONSIDERED
  • FIGURE 3 ANTIBODY DISCOVERY SERVICES MARKET: RESEARCH DESIGN
  • FIGURE 4 ANTIBODY DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
  • FIGURE 5 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 COMPANY REVENUE ANALYSIS-BASED MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC (US), 2024
  • FIGURE 8 ANTIBODY DISCOVERY SERVICES MARKET SIZE VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 9 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 ANTIBODY DISCOVERY SERVICES MARKET: CAGR PROJECTIONS
  • FIGURE 11 ANTIBODY DISCOVERY SERVICES MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 ANTIBODY DISCOVERY SERVICES MARKET: REGIONAL SNAPSHOT
  • FIGURE 18 SNAPSHOT: GLOBAL ANTIBODY DISCOVERY SERVICES MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION)
  • FIGURE 19 INCREASING VENTURE FUNDING AND INVESTMENTS TO DRIVE MARKET
  • FIGURE 20 US AND MONOCLONAL ANTIBODIES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
  • FIGURE 21 MONOCLONAL ANTIBODIES TO ACCOUNT FOR LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
  • FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
  • FIGURE 23 ANTIBODY ENGINEERING & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 24 ANTIBODY DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 ANTIBODY DISCOVERY SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 26 ANTIBODY DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 ANTIBODY DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 28 NIH FUNDING FOR ANTIBODY DISCOVERY, 2014-2025 (USD MILLION)
  • FIGURE 29 TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2014-DECEMBER 2024
  • FIGURE 30 ANTIBODY DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE
  • FIGURE 32 KEY BUYING CRITERIA FOR MAJOR END USERS
  • FIGURE 33 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
  • FIGURE 34 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 35 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, 2020-2024 (USD MILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET (2024)
  • FIGURE 38 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 39 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 40 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 41 EV/EBITDA OF KEY PLAYERS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • FIGURE 43 ANTIBODY DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS
  • FIGURE 44 WUXI BIOLOGICS: COMPANY SNAPSHOT
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 47 EVOTEC: COMPANY SNAPSHOT
  • FIGURE 48 BIOCYTOGEN: COMPANY SNAPSHOT
  • FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • FIGURE 50 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES): COMPANY SNAPSHOT
  • FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
  • FIGURE 52 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
  • FIGURE 53 GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 54 TWIST BIOSCIENCE: COMPANY SNAPSHOT
  • FIGURE 55 HARBOUR BIOMED: COMPANY SNAPSHOT
  • FIGURE 56 ARAGEN LIFE SCIENCES LTD.: COMPANY SNAPSHOT
  • FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 58 VIVA BIOTECH: COMPANY SNAPSHOT
  • FIGURE 59 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY SNAPSHOT
  • FIGURE 60 FUSION ANTIBODIES: COMPANY SNAPSHOT